Table 3.
Middle ring and right side ring modified EP2 antagonists. Potency and aqueous solubilitya
| Compound ID | ![]() |
EP2 KB (nM) | Aqueous Solubilityb (μM) |
|---|---|---|---|
| 20a | ![]() |
10.7 | 27 |
| 20b | ![]() |
8.0 | 25 |
| 20c | ![]() |
6.4 | 15 |
| 20d | ![]() |
44.5 | 5 |
| 20e | ![]() |
6.1 | 25 |
| 20f | ![]() |
96 | 41 |
| 20g | ![]() |
230 | 13 |
| 20h | ![]() |
7.8 | 15 |
| 20i | ![]() |
1220 | 10 |
| 20j | ![]() |
32.5 | 5 |
| 20k | ![]() |
104 | ND |
| 20l | ![]() |
166 | ND |
| 20m | ![]() |
39 | 6 |
| 20n | ![]() |
79.3 | 25 |
| 20o | ![]() |
9.7 | 15 |
| 20p | ![]() |
>1000 | 38 |
| 20q | ![]() |
8.3 | 17 |
| 20r | ![]() |
88.1 | 100 |


















